Preferred Imaging for Primary Hyperparathyroidism
Ultrasound (US) of the parathyroid glands combined with Tc-99m sestamibi scintigraphy with SPECT/CT represents the preferred first-line imaging approach for evaluating primary hyperparathyroidism.
First-Line Imaging Strategy
The 2021 ACR Appropriateness Criteria explicitly state that both the American Head and Neck Society Endocrine Surgery Section and the American Association of Endocrine Surgeons recommend ultrasound as the preferred initial localization study in patients with primary hyperparathyroidism, with the added advantage of concurrent thyroid evaluation 1.
Ultrasound Performance
- Pooled sensitivity: 76-80% with PPV of 93% 1
- Zero radiation exposure 2
- Allows simultaneous thyroid assessment
- Most cost-effective option
However, ultrasound alone is insufficient. The optimal first-line approach combines US with nuclear medicine imaging.
Nuclear Medicine: The Critical Second Component
Sestamibi SPECT/CT (Preferred Nuclear Medicine Option)
The addition of SPECT/CT to dual-phase sestamibi scanning provides superior anatomic localization compared to planar imaging alone 1. When combined with pertechnetate subtraction, this achieves:
- Sensitivity: 93%
- PPV: 96% 1
The dual-tracer approach (sestamibi + pertechnetate) with SPECT/CT outperforms dual-phase sestamibi SPECT/CT alone (88% sensitivity, 92% PPV) 1. This is particularly important in patients with concomitant thyroid disease, where sensitivity increases from 80% to 94% with the addition of CT 1.
Radiation exposure: 8.6-12.1 mSv 2
Emerging Alternative: 18F-Fluorocholine PET/CT
Recent evidence shows 18F-fluorocholine PET/CT demonstrates exceptional performance:
- Detection rate: 97.6% per lesion 3
- Superior to sestamibi SPECT/CT (78.5%) and ultrasound (71.4%) 3
- Radiation exposure: 6.7-11.8 mSv 2
However, fluorocholine PET/CT has important limitations: false positives occur with inflammatory lesions and mediastinal lymph nodes, and it lacks simultaneous thyroid assessment 4. While some advocate for it as first-line imaging, this remains controversial and is not yet endorsed by major surgical societies 4.
Algorithmic Approach
Step 1: Perform neck ultrasound + sestamibi with SPECT/CT (preferably dual-tracer with pertechnetate)
Step 2: If both studies are concordant and positive:
- PPV for correct side: 99% 5
- Proceed to surgery with confidence
Step 3: If initial imaging is negative, equivocal, or discordant:
- Perform 18F-fluorocholine PET/CT as second-line imaging 6, 7
- Alternative: 4D-CT (radiation: 9.3-20.2 mSv) or MRI neck 1
Critical Pitfalls to Avoid
Factors that decrease imaging sensitivity:
- Multiglandular disease (MGD) - reduces sestamibi sensitivity from 71% to 64% 1
- Concomitant thyroid nodular disease 1
- Small adenomas (<500 mg) 1
- Ectopic or posterior location 1
- Mild hypercalcemia 1
In these challenging scenarios, the dual-tracer SPECT/CT protocol is least negatively impacted 1.
Special Populations
Pediatric patients: Ultrasound sensitivity improves with age (93% in older children vs. false negatives in neonates). Sestamibi adds minimal value except in older children with sporadic single adenomas 1.
Reoperative cases: Consider selective venous sampling for PTH if noninvasive imaging yields nonlocalizing or discordant results 1.
Cost and Radiation Considerations
When making imaging decisions, balance:
- Radiation exposure: US (0 mSv) < fluorocholine PET/CT (6.7-11.8 mSv) < sestamibi SPECT/CT (8.6-12.1 mSv) < 4D-CT (9.3-20.2 mSv) 2
- Sensitivity/specificity for adenoma detection
- Local institutional expertise
- Cost-effectiveness
The combination of ultrasound plus sestamibi SPECT/CT remains the evidence-based standard endorsed by surgical societies 1, with fluorocholine PET/CT reserved for second-line evaluation when initial imaging fails to localize the adenoma 6, 7.